New Inotropic Drugs for the Treatment of Heart Failure
Treatment of congestive heart failure consists of to salt restriction, diuretics, digitalis glycosides and recently, vasodilators. However, reports indicate that the prognosis of heart failure is similar to that of most solid cancers (1). Oral inotropic therapy has been limited to digitalis glycosides for nearly 200 years. Nevertheless, there is still considerable controversy over the efficacy of the drug for acute and chronic failure. Several studies suggest that withdrawal of digitalis does not change the clinical status of most patients (2,3). Fleg et al reported in a double blinded placebo controlled trial that oral digoxin did not increase exercise tolerance or improve left ventricular function (4). In addition, the high frequency of digitalis toxicity has prompted a search for safer, more potent agents to increase contractility. In this paper, the inotropic agents under investigation will be reviewed (Table 1).
KeywordsSevere Heart Failure Inotropic Agent Severe Congestive Heart Failure Left Ventricular Filling Pressure Ventricular Filling Pressure
Unable to display preview. Download preview PDF.
- 5.Jamieson SW, Oyer PE, Bieber CP, Stinson EB, Shumway NE: Transplantation for cardiomyopathy: A review of the results. Heart Transplantation (2): 28–31, 1982.Google Scholar
- 6.Osnes JB, Skomedol T, Oye I: On the role of cyclic nucleotides in the heart muscle contraction and relaxation. Prog Pharmacol (4): 47–62, 1980.Google Scholar
- 9.Leier CV, Heban PT, Huss P, Bush CA, Lewis RP: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circ (58): 466–475, 1978.Google Scholar
- 10.Mikulic E, Cohn, JN, Franciosa JA: Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. Circ (56): 528–533, 1977.Google Scholar
- 15.Dahmen M, Greeff K: Analysis of the positive-inotropic activity of the benzimidazole derivate AR-L 115 BS in isolated guinea pig atria. Arzeini-Forsch (Drug Res) (31): 161–165, 1981.Google Scholar
- 23.LeJemtel TH, Keung E, Sonnenblick EH, Ribner HS, Matsumoto M, David R, Schwartz W, Alousi AA, Davolos D: Amrinone: A new non-glycosidic, Non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circ (59): 1098–1104, 1979.Google Scholar
- 28.Naccarelli GV, Gray EL, Dougherty AH, Hanna JF, Goldstein RA: Amrinone: Electrophysiologic effects. Circ (68) (Suppl III): III–128, 1983.Google Scholar
- 29.Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, Braunwald E, Grossman W: Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure/ N Engl J Med (309): 748–756, 1983.Google Scholar
- 30.Maskin CS, Sinoway L, Chadwick B, Sonnenblick EH, LeJemtel TH: Sustained hemodynamic and cllinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circ (67): 1065–1070.Google Scholar